If 2016 was the year that med tech players bet big on emerging and exciting technologies, 2017 will be the year to buckle down, generate evidence of the new tech’s utility and find its niche in the industry, according to FierceBiotech.

This year, numerous companies made moves in artificial intelligence, while GlaxoSmithKline and Verily threw down $715 million on a bioelectronics-oriented joint venture.

Meanwhile, M&A and venture capital funding took a dip, and a few events highlighted current and future cybersecurity risks that may materialize as med tech becomes more connected.